Synthego and bit.bio expand strategic partnership

Synthego and bit.bio expand strategic partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therapies

• Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies.
• bit.bio aims to leverage technology to increase efficiency of human cell engineering and accelerate the development of highly scalable cell therapies that are capable of treating millions of patients.

REDWOOD CITY, CA, 06:00 EDT and Cambridge, UK 11:00 BST, 24 August 2023: Synthego, a leading provider of industrialised genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centred on the implementation of synthetic circuitry in cells for therapeutic application. 

bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego’s expertise in gene editing to bit.bio's opti-ox™ precision cell programming technology, with the aim of discovering and developing advanced genetic engineering solutions for cell therapies.

“bit.bio is the leading synthetic biology company focussed on human cells. We are thrilled to deepen our partnership with bit.bio to facilitate a leap forward in the development of synthetic biology-based cell therapies. By coordinating our respective technologies, expertise and resources, we will unlock new opportunities for addressing critical challenges in the field by advancing the R&D cycle of innovative cell therapies.”

Paul DabrowskiCEO at Synthego

Synthego will rapidly design, build, test and deliver an end-to-end optimised multiplexed genetic editing strategy. The implementation of the multiplexed opti-ox engineering approach will reduce the number of engineering steps required, with the potential of shortening clinical cell engineering and development timelines by up to 10 months. 

"Synthego are experts when it comes to industrialised cell engineering. Teaming up with Synthego will boost our genetic engineering capabilities. We expect efficiency gains across bit.bio’s platform which will allow us and our partners to deliver transformative therapies more rapidly to patients in need.”

Mark KotterCo-founder and CEO, bit.bio

Notes to Editors

About Synthego

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms and products for science at scale. With its foundations in engineering disciplines, the company’s platform technologies vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale.